



 Get Print Book

Development of Antibody-Based Therapeutics: Translational Considerations

From Springer



Download



Read Online

Development of Antibody-Based Therapeutics: Translational Considerations From Springer

Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics.



[Download Development of Antibody-Based Therapeutics: Transl ...pdf](#)



[Read Online Development of Antibody-Based Therapeutics: Tran ...pdf](#)

Development of Antibody-Based Therapeutics: Translational Considerations

From Springer

Development of Antibody-Based Therapeutics: Translational Considerations From Springer

Translational strategies for development of antibody-based therapeutics should allow understanding of the relationship between the 'unit dose' and 'unit effect' with respect to both beneficial and deleterious effects from early stages of development. The flow of information from later to earlier stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Selection and evaluation of relevant biomarkers in early preclinical development in "relevant" animal models should allow for identifying potential risks to humans and establishing safe First-In-Human (FIH) dosing strategies. Hence, integration of knowledge with respect to target antigen properties such as antigen distribution, expression profile, kinetic properties, target pharmacology, antigen isoforms and pharmacological redundancy in health and disease, as well as antibody design criteria, such as antibody isotype, affinity, PK/PD and safety is a critical necessity for the design of effective translational strategies. Additionally, these factors will further offer critical differentiating characteristics for next-generation antibodies, and novel technologies prove instrumental in generation of biosuperior antibody candidates for market entry. This book will examine many important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics.

Development of Antibody-Based Therapeutics: Translational Considerations From Springer Bibliography

- Sales Rank: #1382382 in Books
- Published on: 2012-04-24
- Original language: English
- Number of items: 1
- Dimensions: 9.30" h x 1.30" w x 6.40" l, 1.65 pounds
- Binding: Hardcover
- 426 pages

 [Download Development of Antibody-Based Therapeutics: Transl ...pdf](#)

 [Read Online Development of Antibody-Based Therapeutics: Tran ...pdf](#)

Editorial Review

From the Back Cover

Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the ‘unit dose’ and ‘unit effect’ with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in “relevant” animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.

About the Author

Mohammad Tabrizi, Ph.D., Vice President, Preclinical Development, AnaptysBio Inc. Mohammad Tabrizi is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies. He is currently the Vice President of Preclinical Development at AnaptysBio, Inc., a privately held biotechnology company in San Diego CA, USA, the leader in Somatic HyperMutation (SHM) for development of therapeutic antibodies where he advances the preclinical development efforts.

Gadi Gazit Bornstein, Ph.D., Principal Scientist, AstraZeneca R&D Boston Dr. Bornstein has experience in research and development with an emphasis in development of therapeutic monoclonal antibodies in oncology. Dr. Bornstein is a Principal Scientist at AstraZeneca, where he currently leads several antibody programs within the Preclinical oncology portfolio. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the Keck School of Medicine of the University of Southern California. Dr. Bornstein completed his postdoctoral training at Stanford University School of Medicine in the Division of Immunology and Rheumatology. Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology Department. During his tenure at Abgenix, he was a project team leader and lead biologist for multiple antibody programs.

Scott L. Klakamp, Ph.D., Research Fellow, Biophysical Chemistry and Research Informatics, Takeda San Francisco Scott Klakamp is one of the leading scientists in utilizing Biacore®, KinExA®, and FACS techniques to measure the binding kinetics and equilibrium constants of human monoclonal antibody/antigen complexes. He has extensive experience in research and development involving the biophysical and analytical characterization of biologics and monoclonal antibodies (mAb). He has also contributed significantly to the clinical immunology field by applying highly rigorous analytical detection concepts,

previously unknown to the discipline, to immunogenicity studies of therapeutic mAbs. Currently, he is a Research Fellow at Takeda San Francisco, the therapeutic monoclonal antibody discovery engine for Takeda Pharmaceutical Company, and leads the Biophysical Chemistry and Research Informatics Groups.

Users Review

From reader reviews:

Marlene Childs:

Book is to be different for each grade. Book for children right up until adult are different content. As it is known to us that book is very important for all of us. The book Development of Antibody-Based Therapeutics: Translational Considerations had been making you to know about other understanding and of course you can take more information. It is rather advantages for you. The publication Development of Antibody-Based Therapeutics: Translational Considerations is not only giving you much more new information but also for being your friend when you truly feel bored. You can spend your own personal spend time to read your guide. Try to make relationship with all the book Development of Antibody-Based Therapeutics: Translational Considerations. You never sense lose out for everything when you read some books.

John Judge:

Do you really one of the book lovers? If yes, do you ever feeling doubt if you are in the book store? Make an effort to pick one book that you never know the inside because don't ascertain book by its cover may doesn't work here is difficult job because you are afraid that the inside maybe not because fantastic as in the outside appearance likes. Maybe you answer could be Development of Antibody-Based Therapeutics: Translational Considerations why because the wonderful cover that make you consider in regards to the content will not disappoint a person. The inside or content is usually fantastic as the outside or even cover. Your reading sixth sense will directly show you to pick up this book.

Sharon Hafer:

Are you kind of hectic person, only have 10 or 15 minute in your day to upgrading your mind talent or thinking skill also analytical thinking? Then you are experiencing problem with the book when compared with can satisfy your short period of time to read it because all of this time you only find guide that need more time to be read. Development of Antibody-Based Therapeutics: Translational Considerations can be your answer as it can be read by a person who have those short free time problems.

Marion Driskell:

Is it anyone who having spare time then spend it whole day simply by watching television programs or just telling lies on the bed? Do you need something new? This Development of Antibody-Based Therapeutics: Translational Considerations can be the reply, oh how comes? A fresh book you know. You are and so out of date, spending your free time by reading in this brand-new era is common not a nerd activity. So what these ebooks have than the others?

**Download and Read Online Development of Antibody-Based
Therapeutics: Translational Considerations From Springer
#ZRE5TF1VWIY**

Read Development of Antibody-Based Therapeutics: Translational Considerations From Springer for online ebook

Development of Antibody-Based Therapeutics: Translational Considerations From Springer Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Development of Antibody-Based Therapeutics: Translational Considerations From Springer books to read online.

Online Development of Antibody-Based Therapeutics: Translational Considerations From Springer ebook PDF download

Development of Antibody-Based Therapeutics: Translational Considerations From Springer Doc

Development of Antibody-Based Therapeutics: Translational Considerations From Springer Mobipocket

Development of Antibody-Based Therapeutics: Translational Considerations From Springer EPub